Patent ID: 9045481
Filing Date: 2015-06-02
Classification: A61K,C07D

Abstract:
1. A method for treating pain in a patient which method comprises administering an effective amount of a compound of Formula IB, a pharmaceutically acceptable salt of each thereof, or a pharmaceutical composition comprising a compound of Formula IB or a pharmaceutically acceptable salt thereof: wherein R′ is halo, OR 20 , or C 1 -C 12 alkyl optionally substituted with 1 to 5 R 9 ; R 20 is selected from the group consisting of hydrogen, —C(O)X, —C(O)OX and —C(O)N(Y) 2 where X is C 1 -C 6 alkyl optionally substituted with 1 to 5 R 9 , and each Y is independently selected from the group consisting of hydrogen, C 1 -C 6 alkyl optionally substituted with 1 to 5 R 9 , C 6 -C 14 aryl optionally substituted with 1 to 5 R 9 , C 3 -C 10 cycloalkyl optionally substituted with 1 to 5 R 9 , C 1 -C 10 heteroaryl having 1 to 4 heteroatoms and which is optionally substituted with 1 to 5 R 9 , C 1 -C 10 heterocyclic having 1 to 4 heteroatoms and which is optionally substituted with 1 to 5 R 9 , or where each Y, together with the nitrogen atom bound thereto form either a C 1 -C 6 heterocyclic having 1 to 4 heteroatoms and which is optionally substituted with 1 to 5 R 9 , or a C 1 -C 6 heteroaryl having 1 to 4 heteroatoms and which is optionally substituted with 1 to 5 R 9 ; R 2 is hydrogen; R 3 is selected from the group consisting of hydrogen, —(CH 2 ) m OR 7 , —CR 6 (OH)R 7 , —(CH 2 ) m CN, —(CH 2 ) m COR 7 , —(CH 2 ) m CO 2 R 7 , —(CH 2 ) m C(O)NR 6 R 7 , —(CH 2 ) m C(O)NR 6 NR 7 R 7 , —(CH 2 ) m C(O)NR 6 NR 7 C(O)R 8 , and —(CH 2 ) m NR 6 R 7 ; m is 0, 1, or 2; L is a bond or C 1 -C 12 alkylene; R 4 is selected from the group consisting of, C 1 -C 12 alkyl substituted with 1 to 5 R 9 , C 2 -C 12 alkenyl substituted with 1 to 5 R 9 , —X 2 —R 6 , —(X 2 —Y 2 ) n —X 2 —R 6 , —SO 2 NR 6 R 7 , —O—C(O)R 8 , —C(O)OR 7 , —C(O)NR 6 R 7 , —NR 6 R 7 , —NHC(O)R 8 , and —NR 6 C(O)R 8 ; X 2 is selected from the group consisting of O and S; Y 2 is C 1 -C 4 alkylene or C 6 -C 10 arylene, or a combination thereof; n is 1, 2, or 3; R 6 and R 7 are each independently selected from the group consisting of hydrogen, C 1 -C 12 alkyl optionally substituted with 1 to 5 R 9 , C 1 -C 6 heterocycle having 1 to 4 heteroatoms and which is optionally substituted with 1 to 5 R 9 , C 3 -C 10 cycloalkyl optionally substituted with 1 to 5 R 9 , C 6 -C 10 aryl optionally substituted with 1 to 5 R 9 and C 1 -C 6 heteroaryl having 1 to 4 heteroatoms optionally substituted with 1 to 5 R 9 ; R 8 is selected from the group consisting of C 1 -C 12 alkyl optionally substituted with 1 to 5 R 9 , C 1 -C 6 heterocycle having 1 to 4 heteroatoms optionally substituted with 1 to 5 R 9 , C 3 -C 10 cycloalkyl optionally substituted with 1 to 5 R 9 , C 6 -C 10 aryl optionally substituted with 1 to 5 R 9 and C 1 -C 6 heteroaryl having 1 to 4 heteroatoms optionally substituted with 1 to 5 R 9 ; R 9 is selected from the group consisting of C 1 -C 4 alkyl, phenyl, halo, —OR 10 , —CN, —COR 10 , —CO 2 R 10 , —C(O)NHR 10 , —NR 10 R 10 , —C(O)NR 10 R 10 , —C(O)NHNHR 10 , —C(O)NR 10 NHR 10 , —C(O)NR 10 NR 10 R 10 , —C(O)NHNR 10 C(O)R 10 , —C(O)NHNHC(O)R 10 , —SO 2 NR 10 R 10 , —C(O)NR 10 NR 10 C(O)R 10 , and —C(O)NR 10 NHC(O)R 10 ; and R 10 is C 1 -C 12 alkyl.